For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, Xenon Pharmaceuticals Inc (NASDAQ: XENE) closed at $42.15 up 2.26% from its previous closing price of $41.22. In other words, the price has increased by $2.26 from its previous closing price. On the day, 2.06 million shares were traded. XENE stock price reached its highest trading level at $43.7599 during the session, while it also had its lowest trading level at $41.32.
Ratios:
For a deeper understanding of Xenon Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.52 and its Current Ratio is at 12.52. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On May 07, 2025, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $55.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $67.Deutsche Bank initiated its Buy rating on February 11, 2025, with a $67 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 02 ’26 when MORTIMER IAN sold 40,000 shares for $44.43 per share. The transaction valued at 1,777,093 led to the insider holds 6,000 shares of the business.
IAN MORTIMER bought 40,000 shares of XENE for $1,777,166 on Jan 02 ’26. On Dec 05 ’25, another insider, MORTIMER IAN, who serves as the PRESIDENT & CEO of the company, sold 14,375 shares for $45.03 each. As a result, the insider received 647,306 and left with 16,830 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XENE now has a Market Capitalization of 3257141760 and an Enterprise Value of 2803200512. For the stock, the TTM Price-to-Sale (P/S) ratio is 424.70 while its Price-to-Book (P/B) ratio in mrq is 5.81. Its current Enterprise Value per Revenue stands at 373.76 whereas that against EBITDA is -8.289.
Stock Price History:
The Beta on a monthly basis for XENE is 0.96, which has changed by 0.10196078 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, XENE has reached a high of $46.60, while it has fallen to a 52-week low of $26.74. The 50-Day Moving Average of the stock is -0.71%, while the 200-Day Moving Average is calculated to be 14.63%.
Shares Statistics:
For the past three months, XENE has traded an average of 835.34K shares per day and 1121890 over the past ten days. A total of 77.12M shares are outstanding, with a floating share count of 74.76M. Insiders hold about 3.26% of the company’s shares, while institutions hold 106.82% stake in the company. Shares short for XENE as of 1765756800 were 5720672 with a Short Ratio of 6.85, compared to 1763078400 on 6043619. Therefore, it implies a Short% of Shares Outstanding of 5720672 and a Short% of Float of 8.25.
Earnings Estimates
. The current rating of Xenon Pharmaceuticals Inc (XENE) is the result of assessments by 13.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$1.13, with high estimates of -$0.95 and low estimates of -$1.23.
Analysts are recommending an EPS of between -$4.12 and -$4.55 for the fiscal current year, implying an average EPS of -$4.27. EPS for the following year is -$4.57, with 15.0 analysts recommending between -$2.15 and -$5.33.
